Besides, ARID1A alterations or expression loss could lead to the resistance to EGFR-TKIs via enhancing the EMT, angiogenesis and the inhibition of apoptosis in NSCLC. The gene discussed is ARID1A; the disease is non-small cell lung carcinoma.